Pegylated derivatives of recombinant human arginase (rhArg1) for sustained in vivo activity in cancer therapy: preparation, characterization and analysis of their pharmacodynamics in vivo and in vitro and action upon hepatocellular carcinoma cell (H
about
l-Arginine depletion blunts antitumor T-cell responses by inducing myeloid-derived suppressor cells.High-level expression of human arginase I in Pichia pastoris and its immobilization on chitosan to produce L-ornithineTargeting argininosuccinate synthetase negative melanomas using combination of arginine degrading enzyme and cisplatinStrategies for optimizing the serum persistence of engineered human arginase I for cancer therapy.Activation of Ras/PI3K/ERK pathway induces c-Myc stabilization to upregulate argininosuccinate synthetase, leading to arginine deiminase resistance in melanoma cells.A phase 1 dose-escalating study of pegylated recombinant human arginase 1 (Peg-rhArg1) in patients with advanced hepatocellular carcinoma.Targeted cellular metabolism for cancer chemotherapy with recombinant arginine-degrading enzymes.Development of systemic therapy for hepatocellular carcinoma at 2013: updates and insights.Recombinant arginine-degrading enzymes in metabolic anticancer therapy and bioanalytics.Arginine dependence of tumor cells: targeting a chink in cancer's armor.Involvement of autophagy in recombinant human arginase-induced cell apoptosis and growth inhibition of malignant melanoma cells.Recombinant human arginase inhibits the in vitro and in vivo proliferation of human melanoma by inducing cell cycle arrest and apoptosis.Development and evaluation of a host-targeted antiviral that abrogates herpes simplex virus replication through modulation of arginine-associated metabolic pathways.Preliminary efficacy, safety, pharmacokinetics, pharmacodynamics and quality of life study of pegylated recombinant human arginase 1 in patients with advanced hepatocellular carcinoma.Deprivation of arginine by recombinant human arginase in prostate cancer cells.PEGylation is effective in reducing immunogenicity, immunotoxicity, and hepatotoxicity of α-momorcharin in vivo.An intermolecular disulfide-based light switch for chloroplast psbD gene expression in Chlamydomonas reinhardtii.Expression, purification, and biochemical properties of arginase from Bacillus subtilis 168.
P2860
Q34979666-84CD5E90-4460-4A90-B60A-55DD2ACD8E62Q35727515-31292A25-B370-4CFC-85CC-EAFA9A5F1E2AQ35742521-4F00607C-D098-48A3-8475-F4203FF6E1B9Q35803555-E93CA542-DA77-443E-B9CF-5CDF80724CB3Q36206219-A1ED560A-8998-4DFD-8D37-2F3D3B088EE0Q36557480-BC4AA35C-9876-4C7C-B887-AD68CA59E3A2Q37820202-C3C4C68E-3A64-4092-8A98-EFCEB96D66B9Q38201707-B70B5DD3-E08D-470C-81A2-B242A1A36997Q38250898-65E7E3C4-4B1B-45CD-BBFF-188AD162CABEQ38816145-3D83E869-4B41-44AC-9E7D-EA376F284F07Q39114980-0B84C43E-56E4-459D-9740-4914EC5B7A28Q39823199-B4DA56E0-69BE-4931-BECF-216AFDF3E2D1Q40669532-C03E1596-6A66-4ACD-BF8D-A42537E10E3CQ41457918-137BF4D5-7DF6-4A26-94FB-2248778D8368Q41850297-9822DCD7-0817-4FF2-A7C0-846B20A87A32Q46759580-E343B6CC-CE1A-43AE-97D4-0043ECBAED89Q50494735-51C6917C-8009-4B74-A30E-9020CA7C564AQ51034440-4B9CF305-B14F-4EF1-AC19-4286CD73FD8E
P2860
Pegylated derivatives of recombinant human arginase (rhArg1) for sustained in vivo activity in cancer therapy: preparation, characterization and analysis of their pharmacodynamics in vivo and in vitro and action upon hepatocellular carcinoma cell (H
description
2009 nî lūn-bûn
@nan
2009年の論文
@ja
2009年論文
@yue
2009年論文
@zh-hant
2009年論文
@zh-hk
2009年論文
@zh-mo
2009年論文
@zh-tw
2009年论文
@wuu
2009年论文
@zh
2009年论文
@zh-cn
name
Pegylated derivatives of recom ...... patocellular carcinoma cell (H
@en
type
label
Pegylated derivatives of recom ...... patocellular carcinoma cell (H
@en
prefLabel
Pegylated derivatives of recom ...... patocellular carcinoma cell (H
@en
P2093
P2860
P356
P1476
Pegylated derivatives of recom ...... ocellular carcinoma cell (HCC)
@en
P2093
Denys N Wheatley
Hiu-Chi Chong
Paul Ning-Man Cheng
Pui-Kin So
Simon Arnold
Sui-Yi Kwok
Tin-Lun Lam
Wai-Hung Lo
Wai-Man Lam
P2860
P2888
P356
10.1186/1475-2867-9-9
P577
2009-04-17T00:00:00Z
P5875
P6179
1018933074